Advances in ATM, ATR, WEE1, and CHK1/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer
Qin Tang, Xin Wang, Haixia Wang, Lin Zhong, Dongling Zou
Abstract
Ovarian cancer (OC) poses a significant challenge in modern gynecologic oncology, both diagnostically and therapeutically. According to the American Cancer Society, an estimated 21,000 new cases of OC were reported in the United States alone in 2021[1][1]. The most prevalent subtype of OC87, high-
Topics & Concepts
Ovarian cancerWee1OncologyCancerMedicinePARP inhibitorInternal medicinePoly ADP ribose polymeraseBiologyCell cycleGeneticsDNACyclin-dependent kinase 1PolymerasePARP inhibition in cancer therapyOvarian cancer diagnosis and treatmentDNA Repair Mechanisms